These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23390374)

  • 1. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.
    Gupta A; Nuber N; Esslinger C; Wittenbrink M; Treder M; Landshammer A; Noguchi T; Kelly M; Gnjatic S; Ritter E; von Boehmer L; Nishikawa H; Shiku H; Old L; Ritter G; Knuth A; van den Broek M
    Cancer Immun; 2013; 13():3. PubMed ID: 23390374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells.
    Hu Y; Cheng SC; Chan KT; Ke Y; Xue B; Sin FW; Zeng C; Xie Y
    Biochem Biophys Res Commun; 2010 Feb; 392(3):329-34. PubMed ID: 20067767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.
    Noguchi T; Kato T; Wang L; Maeda Y; Ikeda H; Sato E; Knuth A; Gnjatic S; Ritter G; Sakaguchi S; Old LJ; Shiku H; Nishikawa H
    Cancer Res; 2012 Apr; 72(7):1672-82. PubMed ID: 22318866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
    Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
    Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
    Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
    Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
    Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells.
    Mobergslien A; Vasovic V; Mathiesen G; Fredriksen L; Westby P; Eijsink VG; Peng Q; Sioud M
    Hum Vaccin Immunother; 2015; 11(11):2664-73. PubMed ID: 26185907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
    Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
    J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.
    Susumu S; Nagata Y; Ito S; Matsuo M; Valmori D; Yui K; Udono H; Kanematsu T
    Cancer Sci; 2008 Jan; 99(1):107-12. PubMed ID: 17991294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
    Yuan J; Adamow M; Ginsberg BA; Rasalan TS; Ritter E; Gallardo HF; Xu Y; Pogoriler E; Terzulli SL; Kuk D; Panageas KS; Ritter G; Sznol M; Halaban R; Jungbluth AA; Allison JP; Old LJ; Wolchok JD; Gnjatic S
    Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16723-8. PubMed ID: 21933959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
    Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
    Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.
    Wadle A; Mischo A; Strahl S; Nishikawa H; Held G; Neumann F; Wullner B; Fischer E; Kleber S; Karbach J; Jager E; Shiku H; Odunsi K; Shrikant PA; Knuth A; Cerundolo V; Renner C
    Yeast; 2010 Nov; 27(11):919-31. PubMed ID: 20672253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
    Valmori D; Souleimanian NE; Tosello V; Bhardwaj N; Adams S; O'Neill D; Pavlick A; Escalon JB; Cruz CM; Angiulli A; Angiulli F; Mears G; Vogel SM; Pan L; Jungbluth AA; Hoffmann EW; Venhaus R; Ritter G; Old LJ; Ayyoub M
    Proc Natl Acad Sci U S A; 2007 May; 104(21):8947-52. PubMed ID: 17517626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.